<
Application Data
CytoSelect Cell Migration and Invasion Assay (8 um) Assay Kit
CytoSelect 24-well Cell Migration and Invasion Assay (8 um), Colorimetric, Combo Kit
Synonyms
CytoSelect Cell Migration and Invasion Assay (8 um); N/A; CytoSelect 24-well Cell Migration and Invasion Assay (8 um), Colorimetric, Combo Kit; CytoSelect Cell Migration and Invasion Assay (8 um) assay kit
Preparation and Storage
Store all components at 4 degree C until their expiration dates.
Application Data
Application Data
Application Data
Application Data
Application Data
Application Data
Application Data
Application Data
Related Product Information for CytoSelect Cell Migration and Invasion Assay (8 um) assay kit
Background: Cell migration is a highly integrated, multistep process that orchestrates embryonic morphogenesis, tissue repair and regeneration. It plays a pivotal role in the disease progression of cancer, mental retardation, atherosclerosis, and arthritis. The initial response of a cell to a migration-promoting agent is to polarize and extend protrusions in the direction of the attractant; these protrusions can consist of large, broad lamellipodia or spike-like filopodia. In either case, these protrusions are driven by actin polymerization and can be stabilized by extracellular matrix (ECM) adhesion or cell-cell interactions (via transmembrane receptors). The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the significant morbidity and mortality of cancers. Invasiveness requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Metastatic cells produce many proteolytic enzymes (e.g. lysosomal hydrolysates, collagenases, plasminogen activators) while the expression of certain cell surface protease receptors is also increased. CytoSelect™ Cell Migration Assay utilizes polycarbonate membrane inserts (8 um pore size) to assay the migratory properties of cells. The 8 um pore size is optimal for epithelial and fibroblast cell migration. However, in the case of leukocyte chemotaxis, a smaller pore size (3 um) is recommended. CytoSelect™ Cell Invasion Assay utilizes basement membrane-coated inserts to assay the invasive properties of tumor cells. Each assay contains sufficient reagents for the evaluation of 12 samples.
Product Categories/Family for CytoSelect Cell Migration and Invasion Assay (8 um) assay kit
References
1. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. (2003) Science 302, 1704-9.
2. Horwitz R, Webb D. (2003) Curr Biol. 13, R756-9.
3. Lauffenburger DA, Horwitz AF. (1996) Cell 84, 359-369.
4. Erkell, L. J., Schirrmacher, V. (1988) Cancer Res 48, 6933-6937.
5. Montgomery, A. M. P., De Clerck, Y. A., Langley, K. E., Reisfeld, R. A., Mueller, B. M. (1993) Cancer Res 53,693-700.
6. Monsky, W. L., Lin, C. Y., Aoyama, A., Kelly, T., Akiyama, S. K., Mueller, S. C., Chen, W. T. (1994) Cancer Res 54,5702-5710.
1. Cai, X. Z. et al. (2015). iTRAQ-based quantitative proteomic analysis of nasopharyngeal carcinoma. J Cell Biochem. doi: 10.1002/jcb.25105. 2. Zheng, X. et al. (2015). Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Res. doi: 10.1158/0008-5472. 3. Kim, K. S. et al. (2015). Increased expression of endocan in arthritic synovial tissues: Effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes. Mol Med Rep. 11:2695-2702.
4. Li, M. et al. (2013). Physiological role of the interaction between CARMIL1 and capping protein. Hum. Reprod. 28:2822-2831.
5. Majid, S. et al. (2013). miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer. Res. 19: 73-84.
6. Majid, S. et al. (2012). miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72:6435-6446.
7. Shin, S.Y. et al. (2012). Transcriptional regulation of the Interleukin-11 gene by oncogenic Ras. Carcinogenesis 10.1093/carcin/bgs297.
8. Saini, S. et al. (2012). miRNA-708 control of CD44+ prostate cancer-initiating cells. Cancer. Res. 72: 3618-3630.
9. Dennis, M. et al. (2012). Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngology--Head and Neck Surgery. 147: 726-732.
10. Dalezis, P. et al. (2012). Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model. In Vivo 26:75-86.
11. Kahlert, C. et al. (2011). Overexpression of ZEB2 at the invasion front of colorectal cancer is an Iindependent prognastic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 17:7654-7663.
12. Shin, S.Y. et al. (2010). TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J. Biol. Chem. 285: 30731-30740.
13. Eckstein, N. et al. (2008). EGFR-pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J. Biol. Chem. 283: 739-750.
14. Liu, S. et al. (2008). Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem. 283: 529-540.
15. Ke, X-S. et al. (2008). Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One 3(10):e3368.
16. Isakova, I. et al. (2007). Age and dose-related effects on MSC engraftment levels and anatomical distribution in the CNS of non-human primates: identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 25: 3261-3270.17. Phinney, D. et al. (2006). Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. Stem Cells Dev. 15(3): 437-447.
2. Horwitz R, Webb D. (2003) Curr Biol. 13, R756-9.
3. Lauffenburger DA, Horwitz AF. (1996) Cell 84, 359-369.
4. Erkell, L. J., Schirrmacher, V. (1988) Cancer Res 48, 6933-6937.
5. Montgomery, A. M. P., De Clerck, Y. A., Langley, K. E., Reisfeld, R. A., Mueller, B. M. (1993) Cancer Res 53,693-700.
6. Monsky, W. L., Lin, C. Y., Aoyama, A., Kelly, T., Akiyama, S. K., Mueller, S. C., Chen, W. T. (1994) Cancer Res 54,5702-5710.
1. Cai, X. Z. et al. (2015). iTRAQ-based quantitative proteomic analysis of nasopharyngeal carcinoma. J Cell Biochem. doi: 10.1002/jcb.25105. 2. Zheng, X. et al. (2015). Targeting LunX inhibits non-small-cell lung cancer growth and metastasis. Cancer Res. doi: 10.1158/0008-5472. 3. Kim, K. S. et al. (2015). Increased expression of endocan in arthritic synovial tissues: Effects of adiponectin on the expression of endocan in fibroblast-like synoviocytes. Mol Med Rep. 11:2695-2702.
4. Li, M. et al. (2013). Physiological role of the interaction between CARMIL1 and capping protein. Hum. Reprod. 28:2822-2831.
5. Majid, S. et al. (2013). miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer. Res. 19: 73-84.
6. Majid, S. et al. (2012). miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72:6435-6446.
7. Shin, S.Y. et al. (2012). Transcriptional regulation of the Interleukin-11 gene by oncogenic Ras. Carcinogenesis 10.1093/carcin/bgs297.
8. Saini, S. et al. (2012). miRNA-708 control of CD44+ prostate cancer-initiating cells. Cancer. Res. 72: 3618-3630.
9. Dennis, M. et al. (2012). Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells. Otolaryngology--Head and Neck Surgery. 147: 726-732.
10. Dalezis, P. et al. (2012). Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model. In Vivo 26:75-86.
11. Kahlert, C. et al. (2011). Overexpression of ZEB2 at the invasion front of colorectal cancer is an Iindependent prognastic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 17:7654-7663.
12. Shin, S.Y. et al. (2010). TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J. Biol. Chem. 285: 30731-30740.
13. Eckstein, N. et al. (2008). EGFR-pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J. Biol. Chem. 283: 739-750.
14. Liu, S. et al. (2008). Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J. Biol. Chem. 283: 529-540.
15. Ke, X-S. et al. (2008). Epithelial to mesenchymal transition of a primary prostate cell line with switches of cell adhesion modules but without malignant transformation. PLoS One 3(10):e3368.
16. Isakova, I. et al. (2007). Age and dose-related effects on MSC engraftment levels and anatomical distribution in the CNS of non-human primates: identification of novel MSC subpopulations that respond to guidance cues in brain. Stem Cells 25: 3261-3270.17. Phinney, D. et al. (2006). Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. Stem Cells Dev. 15(3): 437-447.
Similar Products
Product Notes
The CytoSelect Cell Migration and Invasion Assay (8 um) (Catalog #AAA44578) is an Assay Kit and is intended for research purposes only. The product is available for immediate purchase. It is sometimes possible for the material contained within the vial of "CytoSelect Cell Migration and Invasion Assay (8 um), Assay Kit" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.